Announcement PDF Emyria ASX Announcement | 6 October 2026 1 ASX RELEASE. 6 October 2026 INVESTOR WEBINAR WITH FORMER US SECRETARY OF VETERANS AFFAIRS DR DAVID SHULKIN Webinar features Secretary Shulkin’s extensive experience leading large scale healthcare systems and why he has joined Emyria as a Strategic Advisor Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in delivering evidence- based intensive mental-health care, is pleased to provide investors with access to a webinar discussion featuring Executive Chairman, Greg Hutchinson and recently appointed Strategic Advisor, former Secretary David Shulkin. The webinar follows Emyria's recent announcement of former Secretary Shulkin's appointment as Strategic Advisor1 and provides investors with the opportunity to hear directly from former Secretary Shulkin and Mr Hutchinson on the opportunities emerging within the rapidly evolving psychedelic medicine sector. The webinar covers: • Former Secretary Shulkin's background, healthcare leadership experience and rationale for his appointment as Strategic Advisor. • Emyria's clinical delivery model and growing opportunities for the company in the US. • Developments in the US psychedelic medicine landscape. • The importance of clinical data, treatment delivery infrastructure and real-world evidence. • Future potential opportunities for psychedelic-assisted therapies and healthcare system adoption. View the Webinar Here https://emyria.com/webinars/PdxaaP-investor-webinar-with-dr-david-shulkin • Pre-recorded webinar features Emyria Executive Chairman, Greg Hutchinson and newly appointed Strategic Advisor, former 9th United States Secretary of the US Department of Veterans Affairs, Dr David Shulkin. • Former Secretary Shulkin has extensive experience leading large-scale healthcare systems, managing one of the largest healthcare budgets globally, advising governments and healthcare organisations, and supporting healthcare innovation. • The webinar discussion explores former Secretary Shulkin's decision to join Emyria, the evolving psychedelic medicine landscape in the United States, and how his appointment will strengthen Emyria’s strategic US capability to pursue partnerships and commercial opportunities. ASX RELEASE. Emyria ASX Announcement | 6 October 2026 2 Emyria Executive Chair Greg Hutchinson commented: "We are delighted to welcome former Secretary Shulkin as a Strategic Advisor and to provide investors with the opportunity to hear directly from him in this discussion. Former Secretary Shulkin brings exceptional healthcare leadership experience, deep knowledge of healthcare systems and policy, and valuable insight into the evolving US market. We believe his experience will be highly valuable as Emyria continues to expand its engagement with US stakeholders and advance its strategy in the clinical delivery of evidence-based, novel therapies for complex mental health conditions" Reference 1) See ASX announcement 21 September 2026 This announcement has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 436 363 | investors@emyria.com ASX RELEASE. Emyria ASX Announcement | 6 October 2026 3 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs